ArticleJournal for immunotherapy of cancer2026

Correction: Non-superagonist CD28-based dual-signal T cell engager targeting KK-LC-1 enhances antitumor efficacy.

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.